目的探讨人脐血单个核细胞(HUCBMCs)静脉移植联合阿托伐他汀对急性心肌梗死(AMI)模型兔心肌组织血管再生的影响。方法中国家兔AMI模型60只随机分4组,每组15只。对照组:术后24 h生理盐水0.5 m L静脉注射(静注),生理盐水灌胃4周;阿托伐他...目的探讨人脐血单个核细胞(HUCBMCs)静脉移植联合阿托伐他汀对急性心肌梗死(AMI)模型兔心肌组织血管再生的影响。方法中国家兔AMI模型60只随机分4组,每组15只。对照组:术后24 h生理盐水0.5 m L静脉注射(静注),生理盐水灌胃4周;阿托伐他汀组:同时间静注生理盐水0.5 m L,阿托伐他汀5mg/(kg·d)溶入生理盐水灌胃4周;细胞移植组:同时间静注含3×107GFP标记HUCBMCs生理盐水0.5 m L,生理盐水2 m L灌胃4周;联合治疗组:同时间静注含3×107GFP标记HUCBMCs生理盐水0.5 m L,阿托伐他汀5 mg/(kg·d)溶入生理盐水2 m L灌胃4周。移植后分别超声检测左室短轴缩短率(LVFS)、左室射血分数(LVEF);荧光显微镜检测GFP阳性细胞;免疫组织化学检测抗第VⅢ因子染色检测毛细血管密度、血管内皮生长因子(VEGF)。结果 1与对照组、阿托伐他汀组治疗后比较,细胞移植组与联合治疗组LVFS、LVEF改善,联合治疗组改善更加显著;2移植4周后,细胞移植组及联合治疗组梗死区周边可见GFP阳性细胞,后组GFP阳性细胞数量计数多于前组;3与对照组、阿托伐他汀组治疗后比较,移植组及联合治疗组VEGF表达增加,毛细血管密度增加,后组增加幅度显著。结论 HUCBMCs静脉移植联合阿托伐他汀治疗AMI,提高移植细胞在心肌组织内存活率,进一步改善心功能,心肌梗死组织内血管再生增强可能是其联合治疗AMI疗效改善的主要机制之一。展开更多
Cell therapy was proposed as a potential treatment intervention for liver cirrhosis recently due to the fact that the therapeutic protocol for primary biliary cirrhosis (PBC)-associated refractory umbilical hernia and...Cell therapy was proposed as a potential treatment intervention for liver cirrhosis recently due to the fact that the therapeutic protocol for primary biliary cirrhosis (PBC)-associated refractory umbilical hernia and hepatic hydrothorax is not well defined currently. We report herein the case of a 58-year-old woman who received routine treatments for PBC, which developed into an incarcerated hernia and uncontrolled hydrothorax. This subject’s condition was significantly improved and maintained stable condition after receiving human umbilical cord blood-derived mononuclear cell (CBMC) transplantation. Consequently, this new strategy may be a potential treatment option for the refractory umbilical hernia and hydrothorax caused by PBC. However, sufficient data from large-scale controlled and double-blinded clinical trials are needed to further confirm the treatment efficacy and longterm safety before this cell transplantation can be used as a regular therapy for liver cirrhosis.展开更多
文摘[目的]讨论人脐血单个核细胞(human cord blood mononuclear cells,HCMNCs)移植治疗大鼠脊髓损伤后损伤区域轴突再生情况和功能恢复。[方法]利用Impactor ModelⅡ打击器制成30例T10脊髓损伤模型,分组为:实验对照组(DMEM细胞培养基),损伤后3 d HCMNCs移植组,损伤后14 d HCMNCs移植组,每组10例。以HE染色和免疫组化染色以及BDA顺行示踪染色观察脊髓损伤处轴突再生情况,结合对各组实验动物脊髓损伤后肢体功能的恢复情况进行行为学评分(BBB评分),综合评估脊髓功能恢复程度。[结果]与对照组比较,HCMNCs移植治疗能够明显促进神经轴突再生,改善功能恢复,损伤后14 d HCMNCs移植组优于损伤后3 d移植组,各组间疗效差异具有统计学意义(P<0.01)。[结论]HCMNCs在体内向神经元及神经胶质细胞分化,促进神经轴突再生和功能恢复。损伤后14 d是移植的较为理想的时间。
文摘目的探讨人脐血单个核细胞(HUCBMCs)静脉移植联合阿托伐他汀对急性心肌梗死(AMI)模型兔心肌组织血管再生的影响。方法中国家兔AMI模型60只随机分4组,每组15只。对照组:术后24 h生理盐水0.5 m L静脉注射(静注),生理盐水灌胃4周;阿托伐他汀组:同时间静注生理盐水0.5 m L,阿托伐他汀5mg/(kg·d)溶入生理盐水灌胃4周;细胞移植组:同时间静注含3×107GFP标记HUCBMCs生理盐水0.5 m L,生理盐水2 m L灌胃4周;联合治疗组:同时间静注含3×107GFP标记HUCBMCs生理盐水0.5 m L,阿托伐他汀5 mg/(kg·d)溶入生理盐水2 m L灌胃4周。移植后分别超声检测左室短轴缩短率(LVFS)、左室射血分数(LVEF);荧光显微镜检测GFP阳性细胞;免疫组织化学检测抗第VⅢ因子染色检测毛细血管密度、血管内皮生长因子(VEGF)。结果 1与对照组、阿托伐他汀组治疗后比较,细胞移植组与联合治疗组LVFS、LVEF改善,联合治疗组改善更加显著;2移植4周后,细胞移植组及联合治疗组梗死区周边可见GFP阳性细胞,后组GFP阳性细胞数量计数多于前组;3与对照组、阿托伐他汀组治疗后比较,移植组及联合治疗组VEGF表达增加,毛细血管密度增加,后组增加幅度显著。结论 HUCBMCs静脉移植联合阿托伐他汀治疗AMI,提高移植细胞在心肌组织内存活率,进一步改善心功能,心肌梗死组织内血管再生增强可能是其联合治疗AMI疗效改善的主要机制之一。
文摘Cell therapy was proposed as a potential treatment intervention for liver cirrhosis recently due to the fact that the therapeutic protocol for primary biliary cirrhosis (PBC)-associated refractory umbilical hernia and hepatic hydrothorax is not well defined currently. We report herein the case of a 58-year-old woman who received routine treatments for PBC, which developed into an incarcerated hernia and uncontrolled hydrothorax. This subject’s condition was significantly improved and maintained stable condition after receiving human umbilical cord blood-derived mononuclear cell (CBMC) transplantation. Consequently, this new strategy may be a potential treatment option for the refractory umbilical hernia and hydrothorax caused by PBC. However, sufficient data from large-scale controlled and double-blinded clinical trials are needed to further confirm the treatment efficacy and longterm safety before this cell transplantation can be used as a regular therapy for liver cirrhosis.
